Breast Cancer: SWOG S0221 (Iowa Cancer Specialists)

SWOG S0221: Phase III Trial of Continuous Schedule AC +G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Op Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.

Objective

The main purpose of this study is to compare the effects (good and bad) of two different treatments (or “regimens”) for breast cancer that is considered high risk. These two treatments include essentially the same drugs given in different ways and on different schedules. All of the treatments use standard, commercially available medicines that are known to be effective for treating breast cancer.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email